Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biontech Se ADR (NQ: BNTX )

104.64 -1.79 (-1.68%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 22, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Biontech Se ADR

< Previous 1 2 3 4 Next >
Pancreatic Cancer Battle Boosted by $200M VC Firm
EQNX::TICKER_START (NASDAQ:ONCY),(NASDAQ:MACK),(NASDAQ:INCY),(NASDAQ:MRTX),(NASDAQ:BNTX) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Death
Exposures Death
BioNTech and CEPI Announce Partnership to Advance mRNA Mpox Vaccine Development and Support CEPI’s 100 Days Mission
From BioNTech SE
Via GlobeNewswire
Pfizer and BioNTech Receive U.S. FDA Approval for 2023-2024 COVID-19 Vaccine
From Pfizer Inc.
Via Business Wire
3 Stocks to Buy For the COVID Resurgence
The cold and flu season is upon us, but COVID-19 cases and hospitalizations have also increased recently. The Centers for Disease Control (CDC) will be voting 
Via MarketBeat
Exposures COVID-19 Product Safety
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron XBB.1.5-adapted COVID-19 Vaccine in the European Union
From Pfizer Inc.
Via Business Wire
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron XBB.1.5-adapted COVID-19 Vaccine in the European Union
From BioNTech SE
Via GlobeNewswire
BioNTech Expands Management Board by Appointing James Ryan as Chief Legal Officer
From BioNTech SE
Via GlobeNewswire
BioNTech Announces Second Quarter 2023 Financial Results and Corporate Update
From BioNTech SE
Via GlobeNewswire
BioNTech Completes Acquisition of InstaDeep
From BioNTech SE
Via GlobeNewswire
BioNTech to Report Second Quarter 2023 Financial Results and Operational Update on August 7, 2023
From BioNTech SE
Via GlobeNewswire
BioNTech and OncoC4 Initiate Pivotal Phase 3 Trial of BNT316/ONC-392 Program in Metastatic NSCLC
From BioNTech SE
Via GlobeNewswire
BioNTech and OncoC4 Present Positive Phase 1/2 Data for Antibody Candidate BNT316/ONC-392 in Hard-to-Treat NSCLC at ASCO
From BioNTech SE
Via GlobeNewswire
BioNTech Announces First Quarter 2023 Financial Results and Corporate Update
From BioNTech SE
Via GlobeNewswire
BioNTech to Report First Quarter 2023 Financial Results and Operational Update on May 8, 2023
From BioNTech SE
Via GlobeNewswire
Arbutus Biopharma and Genevant Sciences File Patent Infringement Lawsuit Against Pfizer/BioNTech
From Arbutus Biopharma Corporation
Via GlobeNewswire
BioNTech and DualityBio Form Global Strategic Partnership to Accelerate Development of Differentiated Antibody-Drug Conjugate Therapeutics for Solid Tumors
From BioNTech SE
Via GlobeNewswire
BioNTech Announces New ADS Repurchase Program
From BioNTech SE
Via GlobeNewswire
BioNTech Is Ripe For A Rebound In 2023
BioNTech had a strong quarter and may become a takeover target due to its healthy pipeline and a looming patent cliff for big pharma. 
Via MarketBeat
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
BioNTech Announces Fourth Quarter and Full Year 2022 Financial Results and Corporate Update
From BioNTech SE
Via GlobeNewswire
BioNTech and OncoC4 Announce Strategic Collaboration to Co-Develop and Commercialize Novel Checkpoint Antibody in Multiple Solid Tumor Indications
From BioNTech SE
Via GlobeNewswire
BioNTech to Report Full Year and Fourth Quarter 2022 Financial Results and Operational Update on March 27, 2023
From BioNTech SE
Via GlobeNewswire
BioNTech Announces Establishment of Interdisciplinary mRNA Excellence Center to Conduct Research Jointly with Scientists from Weizmann Institute of Science in Israel
From BioNTech SE
Via GlobeNewswire
BioNTech Strengthens Manufacturing Capabilities with First In-House Plasmid DNA Manufacturing Facility
From BioNTech SE
Via GlobeNewswire
Novavax Shares Jumped in January While Others Slipped
Updated FDA Covid vaccine policy could've boosted NVAX shares at the end of January, when other pharma stocks slipped, but it may not affect the bottom line. 
Via MarketBeat
Exposures COVID-19 Product Safety
Mergers and Acquisitions in 2023 Off To A Strong Start
Mergers and acquisitions are common, especially across the health sector. Here are some lesser-known buyouts and how they could fare down the road. 
Via MarketBeat
Exposures Product Safety
BioNTech to Acquire InstaDeep to Strengthen Pioneering Position in the Field of AI-powered Drug Discovery, Design and Development
From BioNTech SE
Via GlobeNewswire
BioNTech Announces Strategic Partnership with UK Government to Provide up to 10,000 Patients with Personalized mRNA Cancer Immunotherapies by 2030
From BioNTech SE
Via GlobeNewswire
BioNTech to Present at the 41st Annual J.P. Morgan Healthcare Conference
From BioNTech SE
Via GlobeNewswire
BioNTech Initiates Phase 1 Clinical Trial for Malaria Vaccine Program BNT165
From BioNTech SE
Via GlobeNewswire
BioNTech and Fosun Pharma Provide COVID-19 Vaccine Doses For Vaccination of German Expatriates in China
From BioNTech SE
Via GlobeNewswire
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.